• Online Features  This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Richard F. Spaide, MD
New York, NY

Arch Ophthalmol. 1994;112(1):19-20.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The ganciclovir intraocular device (GIOD) is an ingenious delivery system that may control cytomegalovirus (CMV) retinitis. The recent article by Anand et al¹ describing the GIOD, however, did not address the issue of patient survival.

The data contained in Figure 1 of the article by Anand et al¹ were used to perform Kaplan-Meier product-limit analysis. Only the data from the first eye of each patient listed to receive therapy with the GIOD were used for survival analysis. These data were also stratified into two groups: those patients who received intravenous ganciclovir sometime in the course of their treatment and those patients who did not. These two groups were compared using the log-rank test.

The median survival for the entire group was 134 days. The median survival for those patients who received intravenous ganciclovir was 249 days. The median survival for those patients not treated with intravenous ganciclovir was . . . [Full Text PDF of this Article]

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?